Genetically Informed Prostate Cancer Treatment for Metastatic Disease

Aisha L Siebert; Brittany M Szymaniak; Yazan Numan; Alicia K Morgans

doi:10.1016/j.ucl.2021.03.006

Genetically Informed Prostate Cancer Treatment for Metastatic Disease

Urol Clin North Am. 2021 Aug;48(3):365-371. doi: 10.1016/j.ucl.2021.03.006. Epub 2021 Jun 10.

Authors

Aisha L Siebert¹, Brittany M Szymaniak², Yazan Numan³, Alicia K Morgans⁴

Affiliations

¹ Department of Urology, Feinberg School of Medicine at Northwestern University, 676 North St. Clair Street, Arkes 23-010, Chicago, IL 60611, USA.
² Department of Urology, Feinberg School of Medicine at Northwestern University, 675 North Saint Clair Street, Suite 20-150, Chicago, IL 60611, USA.
³ Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine at Northwestern University, 676 North St. Clair Street, Suite 850, Chicago, IL 60611, USA.
⁴ Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine at Northwestern University, 676 North St. Clair Street, Suite 850, Chicago, IL 60611, USA. Electronic address: Alicia.morgans@northwestern.edu.

PMID: 34210491
DOI: 10.1016/j.ucl.2021.03.006

Abstract

Germline testing should be performed to support treatment selection for patients with metastatic prostate cancer, and should be identified in patients with high-risk localized disease. Patients with germline BRCA1/2 mutations should be educated regarding additional personal cancer risk, and risk for family members. Guidelines recommend that all men with metastatic prostate cancer should also undergo somatic tissue and germline testing for priority genes BRCA1/2, PALB2, ATM, and MSH2/6. The advent of high throughput sequencing enables patients to be tested for a more comprehensive panel of germline and somatic mutations.

Keywords: DNA-damage repair; Metastatic prostate cancer; Mismatch repair; Targeted treatment.

Publication types

Review

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / therapeutic use
DNA Damage
DNA Repair
Genes, BRCA1
Genes, BRCA2
Genetic Predisposition to Disease*
Genetic Testing
Germ-Line Mutation
Humans
Indoles / therapeutic use
Male
Neoplasm Metastasis / drug therapy
Neoplasm Metastasis / genetics*
Neoplasm Metastasis / pathology*
Phthalazines / therapeutic use
Piperazines / therapeutic use
Prostatic Neoplasms / drug therapy
Prostatic Neoplasms / genetics*
Prostatic Neoplasms / pathology*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Indoles
Phthalazines
Piperazines
rucaparib
pembrolizumab
olaparib